Abstract
Background
To determine the relationship between SIRI, PIV and prognosis in metastatic Non-Small Cell Lung Cancer (NSCLC) and to create a formula based on parameters that can be easily accessed in daily practice.
Methods
A total of 126 patients diagnosed with metastatic NSCLC and receiving systemic chemotherapy were evaluated. Laboratory values measured within 24 hours before the initiation of chemotherapy were recorded. The systemic immune-inflammation index (SIRI) was calculated using the formula (neutrophil count × monocyte count) / lymphocyte count, and the pan-immune-inflammation value (PIV) was obtained using the formula (neutrophil count × platelet count × monocyte count) / lymphocyte count. ROC curve analysis was used to determine the average threshold values for SIRI and PIV. According to the ROC curve, the mean threshold value was established as 2.57 for SIRI and 772 for PIV. Patients with SIRI ≤ 2.57 were classified as SIRI-low, and those with SIRI > 2.57 as SIRI-high. Similarly, patients with a PIV ≤ 772 were classified as PIV-low, and those with a PIV > 772 as PIV-high. Survival analysis was conducted based on the PIV and SIRI cut-off values determined using the ROC curve.
Results
Of the 126 patients included in the study, 100 (79.4%) were male, and 26 (20.6%) were female, with a median age of 64 ± 9.3 years. The median overall survival (mOS) was 17 months in the SIRI-low group, whereas it was 6 months in the SIRI-high group, with a statistically significant correlation between SIRI and survival (p = 0.005). Similarly, the mOS was 19 months in the PIV-low group and 6 months in the PIV-high group, demonstrating a statistically significant relationship between PIV and survival (p = 0.001).
Conclusion
For metastatic NSCLC, the SIRI and PIV can be used to determine prognosis and develop treatment strategies, as it is a clinical decision-making tool based on parameters that are easily accessible in daily practice.